Major trial aims to boost survival for aggressive leukemia

NCT ID NCT07007312

Recruiting now Disease control Sponsor: Kura Oncology, Inc. Source: ClinicalTrials.gov ↗

Summary

This large, late-stage trial is testing whether adding an experimental drug called ziftomenib to standard treatments helps people with newly diagnosed acute myeloid leukemia (AML) who have specific genetic mutations. The study will enroll 1300 adults and has two parts: one for older or less medically fit patients, and another for those who can tolerate stronger chemotherapy. Neither patients nor their doctors will know who receives the new drug or a placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Banner MD Anderson Cancer Center
RECRUITING

Gilbert, Arizona, 85234, United States
Baptist Clinical Research Institute
RECRUITING

Memphis, Tennessee, 38120, United States
Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Icahn School of Medicine at Mount Sinai
RECRUITING

New York, New York, 10003, United States
Moffitt Cancer Center & Research Institute
RECRUITING

Tampa, Florida, 33612, United States
Ohio State University
RECRUITING

Columbus, Ohio, 43210, United States
Rutgers Biomedical and Health Sciences
RECRUITING

New Brunswick, New Jersey, 08903, United States
Tennessee Oncology
RECRUITING

Nashville, Tennessee, 37203, United States
Texas Oncology - San Antonio Medical Center
RECRUITING

San Antonio, Texas, 78240, United States
Texas Oncology-Austin Midtown
RECRUITING

Austin, Texas, 78705, United States
Texas Oncology-Presbyterian Cancer Center
RECRUITING

Dallas, Texas, 75231, United States
TriStar Centennial Medical Center
RECRUITING

Nashville, Tennessee, 37203, United States
University of California, Irvine
RECRUITING

Orange, California, 92868, United States
University of California, San Diego
RECRUITING

La Jolla, California, 92093, United States
University of Kentucky
RECRUITING

Lexington, Kentucky, 40536, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States
University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States
University of New Mexico
RECRUITING

Albuquerque, New Mexico, 87131, United States
University of North Carolina, Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
University of Texas
RECRUITING

Houston, Texas, 77030, United States
University of Virginia School of Medicine
RECRUITING

Charlottesville, Virginia, 22903, United States
Virginia Cancer Specialists
RECRUITING

Manassas, Virginia, 20110, United States
WVU Medicine Wheeling Hospital
RECRUITING

Wheeling, West Virginia, 26003, United States
Wayne State University School of Medicine
RECRUITING

Detroit, Michigan, 48201, United States
Willamette Valley Cancer Institute
RECRUITING

Eugene, Oregon, 97401, United States
Yale University School of Medicine
RECRUITING

New Haven, Connecticut, 06510, United States

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA (AML)